RARE
insider transactionsUltragenyx Pharmaceutical Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-24.0K
0 buy · 24.0K sell
Net value · 90d
-$575.0K
$0 in · $575.0K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
7
0 buy · 24.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director
$50.1K
2.0K sh · $25.05
Own -9%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$46.8K
1.9K sh · $24.62
Own -2%
-
Sell·S
Howard Horn KEY
Chief Financial Officer · 10b5-1
$110.6K
4.7K sh · $23.77
Own -4%
-
Grant·A
Director
$0
120.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Sell·S
Director · 10b5-1
$144.2K
5.7K sh · $25.12
Own -17%
-
Grant·A
Director
$0
14.1K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own +24%
-
Grant·A
Director
$0
14.1K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own +51%
-
Grant·A
Director · 10b5-1
$0
14.1K sh
Own New
-
Grant·A
Director · 10b5-1
$0
7.8K sh
Own +30%
-
Grant·A
Director
$0
14.1K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own +33%
-
Grant·A
Director
$0
14.1K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own +24%
-
Grant·A
Director
$0
14.1K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own +30%
-
Grant·A
Director
$0
14.1K sh
Own New
-
Grant·A
Director
$0
7.8K sh
Own +25%
-
Sell·S
EVP and Chief Medical Officer
$8.6K
344 sh · $24.96
Own -0%
-
Sell·S
Howard Horn KEY
Chief Financial Officer · 10b5-1
$116.6K
4.7K sh · $24.90
Own -4%
-
Grant·A
SVP, Chief Accounting Officer
$0
7.3K sh
Own New
-
Grant·A
SVP, Chief Accounting Officer
$0
20.2K sh
Own +42%
-
Grant·A
EVP, Chief Quality Operations…
$0
79.9K sh
Own New
-
Grant·A
EVP, Chief Quality Operations…
$0
23.1K sh
Own +21%
-
Grant·A
EVP and Chief Legal Officer
$0
50.0K sh
Own New
-
Grant·A
EVP and Chief Legal Officer
$0
28.9K sh
Own +43%
-
Grant·A
Emil D Kakkis KEY
President & CEO
$0
132.7K sh
Own New
-
Grant·A
Emil D Kakkis KEY
President & CEO
$0
76.7K sh
Own +12%
-
Grant·A
EVP, Chief Technical Operatio…
$0
79.9K sh
Own New
-
Grant·A
EVP, Chief Technical Operatio…
$0
23.1K sh
Own +19%
-
Grant·A
Howard Horn KEY
Chief Financial Officer
$0
60.0K sh
Own New
-
Grant·A
Howard Horn KEY
Chief Financial Officer
$0
34.7K sh
Own +43%
-
Grant·A
EVP & Chief Commercial Officer
$0
50.0K sh
Own New
-
Grant·A
EVP & Chief Commercial Officer
$0
28.9K sh
Own +32%
-
Grant·A
EVP and Chief Medical Officer
$0
60.0K sh
Own New
-
Grant·A
EVP and Chief Medical Officer
$0
34.7K sh
Own +45%
-
Sell·S
Howard Horn KEY
Chief Financial Officer · 10b5-1
$98.2K
4.7K sh · $20.97
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Corazon (Corsee) D. Sanders | Sell S | 2.0K | $50.1K |
| Jun 15, 2026 | Karah Herdman Parschauer 10b5-1 | Sell S | 1.9K | $46.8K |
| Jun 1, 2026 | Howard Horn KEY 10b5-1 | Sell S | 4.7K | $110.6K |
| May 28, 2026 | Karah Herdman Parschauer | Grant A | 120.0K | $0 |
| May 27, 2026 | Matthew K Fust | Grant A | 80.0K | $0 |
| May 18, 2026 | Shehnaaz Suliman 10b5-1 | Sell S | 5.7K | $144.2K |
| May 14, 2026 | Daniel G Welch | Grant A | 14.1K | $0 |
| May 14, 2026 | Daniel G Welch | Grant A | 7.8K | $0 |
| May 14, 2026 | Corazon (Corsee) D. Sanders | Grant A | 14.1K | $0 |
| May 14, 2026 | Corazon (Corsee) D. Sanders | Grant A | 7.8K | $0 |
| May 14, 2026 | Shehnaaz Suliman 10b5-1 | Grant A | 14.1K | $0 |
| May 14, 2026 | Shehnaaz Suliman 10b5-1 | Grant A | 7.8K | $0 |
| May 14, 2026 | Amrit Ray | Grant A | 14.1K | $0 |
| May 14, 2026 | Amrit Ray | Grant A | 7.8K | $0 |
| May 14, 2026 | Michael Narachi | Grant A | 14.1K | $0 |
| May 14, 2026 | Michael Narachi | Grant A | 7.8K | $0 |
| May 14, 2026 | Matthew K Fust | Grant A | 14.1K | $0 |
| May 14, 2026 | Matthew K Fust | Grant A | 7.8K | $0 |
| May 14, 2026 | Deborah Dunsire | Grant A | 14.1K | $0 |
| May 14, 2026 | Deborah Dunsire | Grant A | 7.8K | $0 |
| May 5, 2026 | Eric Crombez | Sell S | 344 | $8.6K |
| May 1, 2026 | Howard Horn KEY 10b5-1 | Sell S | 4.7K | $116.6K |
| Apr 22, 2026 | Theodore Alan Huizenga | Grant A | 7.3K | $0 |
| Apr 22, 2026 | Theodore Alan Huizenga | Grant A | 20.2K | $0 |
| Apr 16, 2026 | John Richard Pinion | Grant A | 79.9K | $0 |
| Apr 16, 2026 | John Richard Pinion | Grant A | 23.1K | $0 |
| Apr 16, 2026 | Karah Herdman Parschauer | Grant A | 50.0K | $0 |
| Apr 16, 2026 | Karah Herdman Parschauer | Grant A | 28.9K | $0 |
| Apr 16, 2026 | Emil D Kakkis KEY | Grant A | 132.7K | $0 |
| Apr 16, 2026 | Emil D Kakkis KEY | Grant A | 76.7K | $0 |
| Apr 16, 2026 | Dennis Karl Huang | Grant A | 79.9K | $0 |
| Apr 16, 2026 | Dennis Karl Huang | Grant A | 23.1K | $0 |
| Apr 16, 2026 | Howard Horn KEY | Grant A | 60.0K | $0 |
| Apr 16, 2026 | Howard Horn KEY | Grant A | 34.7K | $0 |
| Apr 16, 2026 | Erik Harris | Grant A | 50.0K | $0 |
| Apr 16, 2026 | Erik Harris | Grant A | 28.9K | $0 |
| Apr 16, 2026 | Eric Crombez | Grant A | 60.0K | $0 |
| Apr 16, 2026 | Eric Crombez | Grant A | 34.7K | $0 |
| Apr 1, 2026 | Howard Horn KEY 10b5-1 | Sell S | 4.7K | $98.2K |
About RARE insider trading
This page tracks insider transactions for Ultragenyx Pharmaceutical Inc. (RARE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.